Identification of Olig2 As Most Specific Glioblastoma Stem Cell Marker Starting from Comparative

Supplementary Table 1. Concordance of three studies comparing the expression profile of GBM cultures enriched in stem cells (“GSC Model” in vitro) compared to serum cultured GBM cells (“Differentiated tumour cells model”) by the technique of DNA microarray.

Gene / Official symbol / References / Expression ratio "GSC Model" in vitro / "Differentiated tumour cells model"
Oligodendrocyte lineage transcription factor 2 /
OLIG2 / 15
171
16* / 5.59
(n=40)
> 3.33
(n=12)
8.75
(GSf, n=31)
3.66
(GSr, n=31)
Protein tyrosine phosphatase, receptor type, Z polypeptide 1 /
PTPRZ1 / 15
171
16* / 3.56
(n=40)
> 3.33
(n=12)
8.68
(GSf, n=31)
7.02
(GSr, n= 31)
Inhibitor of DNA binding 4 /
ID4 / 15
171
16* / 2.87
(n=40)
> 3.33
(n=12)
4.69
(GSf, n=31)
2.21
(GSr, n= 31)
Oligodendrocyte transcription factor 1 /
OLIG1 / 15
16* / 5.63
(n=40)
9.98
(GSf, n=31)
4.14
(GSr, n=31)
Cyclin D2 /
CCND2 / 15
16* / 5.98
(n=40)
6.76
(GSf, n= 31)
2.11
(GSr, n=31)
Aquaporin 4 /
AQP4 / 15
16* / 6.32
(n=40)
6.10
(GSf, n=31)
1.64
(GSr, n=31)
Neurocan /
CSPG3 = NCAN / 15
16* / 4.48
(n=40)
7.75
(GSf, n= 31)
2.33
(GSr, n=31)
Sex determining region Y – box 2 /
SOX2 / 15
16* / 3.45
(n=40)
8.03
(GSf, n=31)
6.56
(GSr, n=31)
Chondroitin sulfate proteoglycan 5 (Neuroglycan 5) /
CSPG5 / 171
16* / > 3.33
(n=12)
7.62
(GSf, n=31)
3.58
(GSr, n=31)
Fatty acid binding protein 7 /
FABP7 / 171
16* / > 3.33
(n=12)
7.32
(GSf, n= 31)
5.73
(GSr, n=31)
Tweety homolog 1 /
TTYH1 / 171
16* / > 3.33
(n=12)
7.41
(GSf, n= 31)
1.90
(GSr, n=31)
Bone morphogenetic protein 7 /
BMP7 / 15
16* / 4.26
(n=40)
5.63
(GSf, n=31)
2.58
(GSr, n=31)
Glycoprotein M6B /
GPM6B / 171
16* / > 3.33
(n=12)
6.47
(GSf, n= 31)
4.74
(GSr, n=31)
Delta-like 1 /
DLL1 / 15
16* / 5.07
(n=40)
3.80
(GSf, n=31)
1.42
(GSr, n=31)
Paraneoplastic antigen MA2 /
PNMA2 / 171
16* / > 3.33
(n=12)
5.97
(GSf, n= 31)
3.12
(GSr, n=31)
WSC domain containing 1 /
WSCD1 / 171
16* / > 3.33
(n=12)
5.785
(GSf, n= 31)
1.745
(GSr, n=31)
Neuro-oncological ventral antigen 1 /
NOVA1 / 171
16* / > 3.33
(n=12)
5.33
(GSf, n=31)
3.30
(GSr, n=31)
Solute carrier family 4, sodium bicarbonate cortransporter, member 4 /
SLC4A4 / 171
16* / > 3.33
(n=12)
5.28
(GSf, n=31)
2.81
(GSr, n=31)
Reticulon 1 /
RTN1 / 171
16* / > 3.33
(n=12)
5.30
(GSf, n=31)
6.61
(GSr, n=31)
Growth associated protein 43 /
GAP43 / 171
16* / > 3.33
(n=12)
5.11
(GSf, n=31)
4.84
(GSr, n=31)
Glycoprotein M6A /
GPM6A / 171
16* / > 3.33
(n=12)
4.86
(GSf, n=31)
Sprouty homolg 1 antagonist of FGF signaling /
SPRY1 / 171
16* / > 3.33
(n=12)
4.40
(GSf, n=31)
4.39
(GSr, n=31)
LIM domain only 2 /
LMO2 / 15
16* / 3.28
(n=40)
4.28
(GSf, n=31)
2.72
(GSr, n=31)
Spermatogenesis
associated 6 /
SPATA6 / 15
16* / 3.80
(n=40)
3.72
(GSf, n=31)
1.52
(GSr, n=31)
Hairy/enhancer-of-split related with YRPW motif 1 /
HEY1 / 171
16* / > 3.33
(n=12)
3.73
(GSf, n=31)
3.70
(GSr, n=31)
Roundabout axon guidance receptor homolog 2 /
ROBO2 / 15
16* / 2.35
(n=40)
4.47
(GSf, n=31)
Chemokine (C-X-C motif) receptor 4 /
CXCR4 / 15
16* / 3.96
(n=40)
2.94
(GSf, n=31)
2.83
(GSr, n=31)
Collagen type IX alpha 3 /
COL9A3 / 171
16* / > 3.33
(n=12)
3.48
(GSf, n= 31)
6.04
(GSr, n=31)
Solute carrier family 15 membre 2 /
SLC15A2 / 15
16* / 3.91
(n=40)
2.75
(GSf, n=31)
1.55
(GSr, n=31)
Sal-like 1 /
SALL1 / 171
16* / > 3.33
(n=12)
3.26
(GSf, n=31)
2.06
(GSr, n=31)
Prospero homeobox 1 /
PROX1 / 15
16* / 3.05
(n=40)
2.95
(GSf, n=31)
2.30
(GSr, n=31)
Encoding prominin 1 /
PROM1 = CD133 / 15
16* / 2.98
(n=40)
2.44
(GSf, n=31)

All values are expressed as log2 expression ratio ("GSC models" / "Differentiated tumour cells model"). Selection of genes for which log2 expression ratio -2 or > 2.

Legend :

- Gene : gene proposed in the literature to identify GSCs

- GSC : glioma stem cell

- n: number of samples studied.

- Distinction of GSCs into GSf and GSr as proposed by Schulte et al. (16)

- GSf: growth as neurospheres in vitro, expression of CD133, high tumourigenic and invasion potential and proneural gene expression signature.

- GSr: adherent growth in vitro, no expression of CD133, smaller tumourigenic and invasion potential and mesenchymal gene expression signature.

- * Expression ratios calculated from the raw data (GEO DataSets number access : GSE23806).

- 1 Expression ratios could be significantly higher than mentioned (no access to raw data available)